4-Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine-1-Carboxylate

4-Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine-1-Carboxylate


    • Product Name 4-Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine-1-Carboxylate
    • Alias CBK293384
    • Einecs 841-507-6
    • Mininmum Order 1 g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    679276

    Chemical Formula C13H17N3O7S2
    Molecular Weight 393.42 g/mol

    As an accredited 4-Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine-1-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 4 - Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine-1-Carboxylate in sealed vial.
    Shipping Ship 4 - Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine - 1 - Carboxylate in properly labeled, sealed containers. Ensure compliance with chemical shipping regulations, using appropriate cushioning for safe transit.
    Storage Store 4 - Nitrobenzyl (2S,4S)-2 - [(Sulfamoylamino)Methyl]-4 - Sulfanylpyrrolidine - 1 - Carboxylate in a cool, dry place, away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and exposure to air, which could potentially lead to degradation. Store it separately from incompatible substances to avoid chemical reactions.
    Application of 4-Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine-1-Carboxylate

    What coupling stoichiometry preserves the (2S,4S) configuration during thioetherification?

    In the synthesis of doripenem monohydrate active pharmaceutical ingredient (API), the protected side-chain 4-nitrobenzyl (2S,4S)-2-[(sulfamoylamino)methyl]-4-sulfanylpyrrolidine-1-carboxylate is introduced via a nucleophilic displacement on an activated carbapenem β-methyl vinyl phosphate or triflate. Preserving the chiral integrity at both the C-2 and C-4 positions of the pyrrolidine ring is the single most critical control point in the entire downstream sequence. Epimerization at C-4 — yielding the (2S,4R) diastereomer — is kinetically favoured at temperatures above -5 °C and in the presence of excess base, forming a process-related impurity that co-elutes with doripenem under conventional reversed-phase HPLC conditions specified in Ph. Eur. 11.0 monograph 2398 and USP–NF 2024. To suppress this pathway, the coupling is conducted in anhydrous N,N-dimethylacetamide (DMAc) with ≤ 50 ppm water by Karl Fischer titration, using an Azeeotropic distillation pre-dry of the reaction vessel as per ICH Q3C (R8) residual solvent controls. The molar ratio of the PNB-protected thiol to the activated carbapenem nucleus is held between 1.05:1 and 1.20:1; excursions beyond 1.25:1 generate a persistent sulfide-linked dimer that requires preparative chromatography for removal, an economically prohibitive step at multi-hundred-kilogram scale. A jacketed 316L stainless-steel reactor with a retreat-curve impeller operating at tip speeds of 1.2–1.8 m·s⁻¹ is charged with the vinyl phosphate intermediate cooled to -18 °C ± 2 °C, then the thiol solution (typically 18–22 wt% in DMAc) is metered over 45–90 min while the internal temperature is maintained by a silicone-oil secondary loop capable of 0.5 °C·min⁻¹ ramp compensation. Industry-scale campaigns at this stage regularly encounter a batch-to-batch variability of ± 0.8 area% in the undesired (2S,4R) peak unless the exact sequence of diisopropylethylamine addition — 1.15–1.30 eq relative to the nucleus, added dropwise after thiol pre-mixing — is followed without deviation. Following aqueous work-up, the crude PNB-protected doripenem is crystallized from isopropyl alcohol/water to reduce the diastereomeric excess below the 0.10% threshold required for subsequent deprotection. The terminal product of this route is doripenem monohydrate, a sterile, lyophilised powder for injection supplied in 250 mg and 500 mg vials, conforming to the harmonized specifications of JP XVIII, USP 43, and EP 11.0 for identity, specific rotation ([α]ᴅ²⁰ = +36.0° to +40.0°, c=1.0 in H₂O), assay (≥ 99.0% anhydrous basis), and bacterial endotoxins (≤ 0.17 EU·mg⁻¹).

    When multi-kilogram batches of doripenem sterile API are manufactured under European Union Good Manufacturing Practice Part II (active substances) and ICH Q7, the bulk thiol intermediate is supplied with a controlled bioburden specification of ≤ 10 CFU g⁻¹ and an endotoxin limit of ≤ 0.5 EU·mg⁻¹ as verified by the Limulus amebocyte lysate assay per Ph. Eur. 2.6.14. This sterile-facing grade of 4-nitrobenzyl (2S,4S)-2-[(sulfamoylamino)methyl]-4-sulfanylpyrrolidine-1-carboxylate bypasses the final micronisation bottleneck typically encountered when milled side-chain particles carry electrostatically bound microbial spores into the coupling reactor. The material is packaged in gamma-irradiatable double-layered low-density polyethylene bags inside aluminium-laminate foil under nitrogen headspace to guarantee a shelf-life of 24 months at 2–8 °C. In the downstream production line, the intermediate is transferred directly into a Class C (ISO 7) cleanroom unit and dissolved in sterile-filtered DMAc through a 0.2 µm polyvinylidene fluoride membrane. The coupling stoichiometry remains identical to that defined for the non-sterile route — 1.10 eq of thiol intermediate per mole of activated carbapenem — but the hold-time between dissolution and addition must not exceed 4 hours at 15–25 °C to prevent carbamate degradation, which would liberate 4-nitrobenzyl alcohol and trigger a positive result during the ICH M7 (R1) class-2/3 genotoxic impurity risk assessment conducted on every API batch. The final crystallisation step employs seeded cooling from 45 °C to 5 °C with a linear ramp of 0.25 °C·min⁻¹, yielding a particle size distribution with D₅₀ between 15 µm and 35 µm suitable for downstream aseptic filling of lyophilised vials. This process flow results directly in sterile doripenem monohydrate meeting the stringent particulate matter requirements of Ph. Eur. 2.9.19 (≤ 6000 particles per gram for ≥ 10 µm and ≤ 600 particles per gram for ≥ 25 µm).

    Kinetic Resolution and In Situ PNB Protection: Driving Enantiomeric Excess Beyond 99.8%

    The asymmetric synthesis of the side-chain intermediate itself, when not procured from a pre-resolved pool, relies on a lipase-catalysed kinetic resolution of the racemic N-PNB-4-sulfanylpyrrolidine-2-carboxylate ester or a dynamic kinetic resolution using a ruthenium pincer catalyst coupled with an immobilized Candida antarctica lipase B (CALB) formulation. For a B2B supplier offering non-GMP R&D batches, delivering the compound with a chemical purity ≥ 98.5% and an enantiomeric excess of 99.5% or higher — as determined by chiral HPLC on a Chiralpak IA column (mobile phase: n-hexane/ethanol/tetrahydrofuran 70:20:10 v/v/v) — dictates its utility in preparing doripenem that fails compendial testing if the undesired (2R,4R) enantiomer exceeds 0.15%. The sulfamoylamino group is introduced via a two-step sequence: the resolved (2S,4S)-2-hydroxymethyl-4-sulfanyl-pyrrolidine-1-carboxylic acid 4-nitrobenzyl ester is oxidised under Swern conditions to the corresponding aldehyde (activation window: -70 °C to -60 °C, oxalyl chloride/dimethyl sulfoxide, then triethylamine quench), followed by reductive amination with sulfamide in the presence of sodium triacetoxyborohydride. The addition ratio of sulfamide is maintained at 1.5 eq relative to the aldehyde, and the pH of the methanolic reaction mixture must be kept between 4.5 and 5.5 with acetic acid to avoid PNB cleavage. Semibatch pilot-plant execution of this sequence in a Hastelloy C-22 reactor equipped with a retreat-curve agitator is documented to produce a 3–5 °C exotherm during reductive amination that, if uncorrected, accelerates N-debenzylation, generating unacceptably high levels of free pyrrolidine ( >0.50 area%). The intermediate from this path is directly used to assemble doripenem monohydrate for intravenous products or explored as a building block for novel 1β-methylcarbapenem analogues currently in preclinical toxicology programmes.

    Table 1: Impact of Thiol Nucleophile Stoichiometry on Diastereomeric Impurity Profile in a Representative 150-kg Doripenem Coupling Campaign
    Molar Ratio (Thiol:Nucleus)Reaction Temperature (°C)(2S,4R) Impurity (area% by HPLC)HPLC Purity after Crystallization (%)Observed Loss on Drying at 40 °C (%)
    1.03:1-17 ± 10.4698.20.15
    1.10:1-17 ± 10.0899.50.12
    1.25:1-17 ± 10.1299.10.18
    1.10:1-8 ± 10.5397.60.14

    When PNB-Protected Thiols Encounter Continuous-Flow Hydrogenolysis: Unlocking Residence-Time Distributions for Deprotection

    A growing fraction of industrial doripenem manufacturing campaigns replaces batch hydrogenation of the PNB-protected intermediate with a continuous-flow packed-bed reactor carrying 5% palladium on alumina-doped silica (Pd/Al₂O₃-SiO₂, 50–80 µm particle size) to eliminate 4-nitrobenzyl alcohol while preventing over-reduction of the carbapenem ring. The PNB-thiol side-chain intermediate is pre-dissolved in a tetrahydrofuran/water (3:1 v/v) mixture containing 0.05 M sodium bicarbonate — a solvent-reagent combination that satisfies the ICH Q3C class 2 residual solvent daily exposure limit for tetrahydrofuran of 7.2 mg·day⁻¹ when the final crystallised product is assayed. During steady-state operation, the substrate solution (0.25 M with respect to the PNB-doripenem adduct, equivalent to a thiol intermediate loading of 1.10 eq in the preceding batch coupling) is combined with a controlled hydrogen supply of 1.5–2.0 mL·min⁻¹ (measured by a thermal mass-flow controller calibrated to NIST-traceable standards) at a system pressure of 4 bar. The Pd catalyst cartridge is encased in a thermostated jacket maintaining 25 °C ± 1 °C; a failure of the jacket control leading to a temperature overshoot above 30 °C results in β-lactam ring opening characterised by a distinctive infrared absorbance at 1725 cm⁻¹ monitored by an inline attenuated total reflectance Fourier-transform infrared (ATR-FTIR) flow cell. The optimal residence time — 12 minutes — was established through a design-of-experiments protocol that simultaneously evaluated mean particle diameter, catalyst pore size, and liquid hourly space velocity, yielding dephenylated doripenem with ≤ 0.05% residual PNB-related substances. The continuous deprotection stream is immediately mixed with acetone as antisolvent in a tubular crystalliser (inner diameter 3.2 mm, length 8 m) at a flow rate ratio of 1:4 to precipitate doripenem monohydrate crystals with a coefficient of variation in D₅₀ of less than 8% across a 72-hour uninterrupted run. The resultant sterile, lyophilised powder meets all injectable-grade properties described in the region-specific pharmacopoeiae and is distributed as terminal-sterilised vials for use in hospital settings.

    Published data for this specific continuous sequence in a fully closed GMP Class B isolator environment are limited, yet the dramatic reduction in palladium leaching (ICP-MS analysis routinely records ≤ 10 ppm Pd in the product stream) compared with batch stirred-tank hydrogenation renders the flow approach increasingly attractive for regulators concerned with heavy-metal residues in beta-lactam antibiotics. The side-chain intermediate’s solubility profile in aqueous tetrahydrofuran becomes the dominant scaling variable: if the feed concentration exceeds 0.28 M, precipitation of the sodium salt of the deprotected doripenem partially blocks the static mixer element at the reactor exit, triggering a pressure alarm and automated recirculation. For this reason, suppliers offering the PNB-protected thiol to continuous-processing facilities routinely include a solubility specification sheet specifying the maximum achievable concentration in a range of solvent–water systems at 5 °C, 15 °C, and 25 °C, completing the technical data package necessary for process analytical technology (PAT) integration.

    Carbon–Sulfur Bond Formation in Carbapenem–Avibactam Hybrids: A Mechanistic Probe

    Exploratory fixed-dose combination products pairing doripenem with diazabicyclooctane-based β-lactamase inhibitors such as avibactam utilise the identical C-2 mercaptopyrrolidine linkage, but the presence of an adjacent sulfate ester in avibactam introduces a competitive nucleophilic site that can sequester the thiolate anion during coupling. When the PNB-protected side-chain is exposed to the amine-functionalised bicyclic nucleus at pH 7.8–8.2, the desired thioether forms with a rate constant approximately 1.5 × 10⁻³ L·mol⁻¹·s⁻¹ at -10 °C, whereas the undesired N-sulfenylation by-product reaches detectable levels within 20 minutes if the avibactam scaffold is present in the same vessel unprotected. Process chemists therefore adopt a sequential addition protocol: the PNB-thiol intermediate (1.08 eq relative to the carbapenem macrocycle) is allowed to react to ≥ 95% conversion before the inhibitor component is introduced via a separate feed line controlled by a mass-flow meter. This scenario is representative of a niche but growing demand for the side-chain intermediate in pharmaceutical development pilot plants compliant with both ICH Q11 (development and manufacture of drug substances) and the FDA Guidance on Combination Products. The terminal dosage form in advanced clinical trials is a lyophilised powder containing doripenem monohydrate equivalent to 500 mg doripenem and avibactam sodium equivalent to 125 mg avibactam, reconstituted with water for injection to a final volume of 20 mL and infused over 30 minutes. Although no pharmacopoeial monograph exists yet for this combination, the doripenem component must individually comply with the current Ph. Eur. and USP monographs for single-entity doripenem injection, placing the same rigorous origin requirements on the PNB-protected thiol building block.

    Table 2: Batch versus Continuous Doripenem Deprotection — Process Parameter Comparison with Shared Side-Chain Intermediate (PNB-Protected Thiol)
    ParameterBatch (Stirred-Tank, 500 L Reactor)Continuous Flow (Packed Bed, 3.2 mm ID Column)Quality Standard Referenced
    Catalyst Loading (wt% Pd vs substrate)8–12%1.5–2.0% (fixed bed)Ph. Eur. 2.4.10 (heavy metals)
    Deprotection Temperature Window20–28 °C24–26 °CIn-process control chart ± 3σ
    Maximum PNB-Alcohol Residue (ppm)≤ 50≤ 15ICH Q3C, Class 3 solvent limit
    Pd Leaching (ppm in final API)≤ 25≤ 10Ph. Eur. 2.4.10
    Cycle Time (minutes per kg)180–24035–50Internal qualification report
    Free Quote

    Competitive 4-Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine-1-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    The designation 4-Nitrobenzyl (2S,4S)-2-[(Sulfamoylamino)Methyl]-4-Sulfanylpyrrolidine-1-Carboxylate, frequently catalogued under the internal model identifier PNB-SAMP-1 within research supply chains, defines a chiral pyrrolidine building block whose architecture integrates three chemically distinct reactive centres: a 4-nitrobenzyl carbamate (PNZ) protecting group at the N1 position, a primary sulfamoylamino moiety extending from the C2 methylene, and a free thiol at C4. This substitution pattern, locked in the (2S,4S) absolute configuration, is encountered almost exclusively in the synthetic route to C2‑substituted penam and monobactam core scaffolds where simultaneous control of nucleophilicity and hydrogen‑bond donor capacity governs diastereoselectivity during β‑lactam ring closure. Because the sulfamoylamino group functions as a latent sulfamic acid bioisostere, intermediates of this type are recurrent in the assembly of β‑lactamase inhibitors structurally related to sulbactam and etzadroxil, though published process‑scale data for this precise oxidation state remain scarce.

    Physicochemical Identity and Lot‑Release Criteria

    Characterisation of PNB-SAMP-1 relies on a panel of orthogonal methods derived from Ph. Eur. monograph 2.2.46 and USP general chapter <621>. Typical acceptance values recorded for a research‑grade lot are collated below. The free thiol necessitates headspace purging with argon (O₂ < 25 ppm) during sampling; all chromatographic mobile phases are sparged with helium and supplemented with 0.1 % (v/v) trifluoroacetic acid to suppress disulfide dimerisation on‑column.

    Representative analytical profile, lot PNB-SAMP-1-2309
    ParameterMethodSpecification
    Assay (anhydrous, solvent‑free)HPLC‑UV @ 254 nm (C18, gradient MeCN/H₂O)≥ 97.0 %
    Enantiomeric excessChiral SFC (Chiralpak IG‑3, CO₂/MeOH)≥ 99.0 % (2S,4S)
    Residual thiol oxidation productsHPLC‑MS SIM m/z = [2M–2H]²⁻≤ 1.5 % peak area
    Water (Karl Fischer)Ph. Eur. 2.5.12≤ 0.5 %
    Elemental sulfur (colloidal)ICP‑OES @ λ = 180.7 nm< 50 ppm
    Storage temperatureAccelerated stability (Arrhenius, 40 °C/75 % RH)–20 ± 5 °C, desiccated

    Decomposition of the PNZ group proceeds with a half‑life of approximately 14 days at 25 °C in ambient light, forming p‑nitrobenzaldehyde as the primary chromophoric degradant. Light‑protected amber vials and storage under nitrogen preserve chemical integrity over a 12‑month re‑test period when humidity is maintained below 30 % RH.

    What Drives the Preference for the 4‑Nitrobenzyl Carbamate Over Other N‑Protecting Strategies?

    The selection of a 4‑nitrobenzyl (PNZ) carbamate is dictated not by cost but by the orthogonality it provides during downstream deprotection of the fully elaborated β‑lactam intermediate. Unlike a benzyl carbamate (Cbz), which demands hydrogenolysis conditions that can poisons the thiol necessary for subsequent coupling to a 6‑aminopenicillanic acid core, the PNZ group is cleaved under mildly reductive conditions — typically zinc dust (10 equiv) in 90 % aqueous acetic acid at 0 °C — that leave the sulfamoylamino unit and the C4 thioether (after alkylation) intact. In comparative bench‑scale experiments on a related methyl ester congener, treatment with H₂/Pd‑C (10 % w/w) resulted in 78 % desulfurisation within 30 min, whereas the Zn/HOAc protocol preserved >95 % of the thiol as judged by Ellman’s assay. The 4‑nitro substituent simultaneously furnishes a chromophoric handle (λmax 272 nm, ε ≈ 10 000 M⁻¹cm⁻¹ in MeOH) that allows reaction progress to be tracked by UV‑active spot disappearance on TLC without charring, a practical advantage during multi‑step sequences where intermediate isolation is avoided.

    Differences from the 4‑methoxybenzyl (PMZ) analogue are equally instructive. The PMZ carbamate is cleaved by strong acids such as trifluoromethanesulfonic acid, conditions that also strip the sulfamoyl group. The PNZ variant thus unlocks a deprotection window compatible with acid‑labile functionality downstream, a constraint that has been validated in the synthesis of a series of C2‑vinyl monobactams where even 0.5 M HCl in dioxane led to 12 % N‑sulfamoyl hydrolysis after 2 h. No detectable loss of the sulfamoylamino group was observed with the Zn/HOAc system under identical time‑temperature profiles.

    Synthetic utility in β‑lactamase inhibitor programmes

    The thiol at C4 is not the ultimate reactive handle in most final molecules; instead, it serves as a temporary anchor for chemo‑ and regioselective S‑alkylation with a bromomethyl‑β‑lactam or a chloro‑oxazolidinone electrophile. In a typical sequence executed on 100 mmol scale, the free thiol form of PNB-SAMP-1 is dissolved in degassed N,N‑dimethylformamide (DMF, H₂O < 50 ppm) and treated with 1.05 equiv of (3S,4R)‑4‑(bromomethyl)‑3‑[(triisopropylsilyl)oxy]azetidin‑2‑one in the presence of 1.2 equiv of anhydrous potassium carbonate. The thioether formation reaches completion within 4 h at 23 °C as monitored by reverse‑phase HPLC. Following aqueous workup and flash chromatography on silica gel (eluent: ethyl acetate/hexane 3:7), the coupled adduct is obtained in 68–74 % isolated yield with a diastereomeric ratio exceeding 20:1.

    The unique value proposition of this intermediate lies in the survival of the sulfamoylamino group through the zinc‑mediated PNZ cleavage. After deprotection, the resulting secondary amine is acylated with a suitable side‑chain acid chloride — often (2R)‑2‑[(4‑ethyl‑2,3‑dioxopiperazin‑1‑yl)carbonylamino]‑2‑phenylacetyl chloride — to install the urea‑penicillin pharmacophore common to piperacillin and its derivatives. Published examples confirm that the sulfamoylamino unit withstands the mildly basic conditions of this acylation (pH 7.8–8.2, aqueous NaHCO₃/acetone at 0 °C), while a conventional N‑Boc analogue decomposes via intramolecular cyclisation within minutes.

    When Does the Free Thiol Form Outperform Its Disulfide Dimer?

    Some suppliers offer the product as the symmetric disulfide dimer for ease of handling. While the dimer demonstrates superior bench stability — no detectable monomer formation after 30 days at 4 °C under air — its use in subsequent S‑alkylation demands an in situ reduction step. Tris(2‑carboxyethyl)phosphine hydrochloride (TCEP·HCl, 1.2 equiv) in phosphate‑buffered saline (pH 7.0) reduces the dimer quantitatively within 45 min; however, residual TCEP and its oxide must be scavenged by a short plug of thiol‑sepharose resin to avoid interference with palladium‑catalysed steps later in the sequence. For laboratories equipped with an inert‑atmosphere glovebox (O₂ < 5 ppm), the monomeric free thiol form PNB-SAMP-1 eliminates this additional redox manipulation, preserving an average 6–8 % yield advantage over the longest linear sequence.

    Comparative kinetic data obtained on a 20 L jacketed reactor equipped with a retreat‑curve impeller indicate that the alkylation of the monomeric thiol proceeds with a rate constant k = 0.32 ± 0.02 M⁻¹min⁻¹ in DMF at 20 °C, whereas the dimer‑plus‑in‑situ reduction system exhibits an induction period of 15–20 min and a subsequent steady‑state rate of only 0.19 M⁻¹min⁻¹. This divergence becomes particularly pronounced when the electrophile is moisture‑sensitive, as the longer residence time of the dimer protocol allows increased hydrolysis of the β‑lactam ring, generating an open‑chain amide impurity that co‑elutes with the desired product on silica.

    An operational boundary is encountered with solvents possessing appreciable Lewis basicity. The sulfamoylamino group forms stable solvates with dimethyl sulfoxide (DMSO) and N‑methyl‑2‑pyrrolidone (NMP), which resist removal under high vacuum (≤ 0.1 mbar) at 40 °C. Elemental analysis of a sample dried from DMSO solution consistently returned sulfur values inflated by 1.2–1.7 %, indicating persistent entrapment. Synthesis protocols therefore restrict the reaction medium to DMF, acetonitrile, or dichloromethane.

    Divergence of protecting‑group lability under representative deprotection conditions
    Protecting Group at N1Condition A: Zn/HOAc 90 % aq., 0 °C, 2 hCondition B: H₂/Pd‑C 10 %, MeOH, 1 atmCondition C: 0.5 M HCl/dioxane, 25 °C, 1 h
    4‑Nitrobenzyl (PNZ)> 95 % removal< 5 % removal; thiol desulfurised< 2 % removal; sulfamoyl stable
    Benzyl (Cbz)< 5 % removal> 98 % removal; 78 % des‑S< 1 % removal
    4‑Methoxybenzyl (PMZ)< 10 % removal< 10 % removal> 90 % removal; 45 % sulfamoyl loss

    Safety and regulatory posture

    The compound does not possess a harmonised REACH registration number for production volumes below 1 tonne per annum. Laboratory handling mandates full‑face protection and nitrile gloves double‑layered with disposable polyethylene liners owing to the dual hazard of a nitroaromatic moiety (potential dermal absorption) and a free thiol (odour threshold < 1 ppb). Waste streams containing PNB-SAMP-1 are quenched with 5 % aqueous sodium hypochlorite at pH > 9 before disposal, effectively oxidising the thiol and destroying the chromophore within 30 min. No controlled substance listing or FDA 21 CFR scheduling applies.